{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"The total number of patients who demonstrate a response to treatment. Measured by RECIST 1.1 criteria.","groups":[{"description":"500 mg of dovitinib (5 capsules) once a day for 5 continuous days and stop for 2 days. Continue to take dovitinib capsules in this manner until until progression or unacceptable toxicity develops.","id":"OG000","title":"Dovitinib"}],"paramType":"NUMBER","populationDescription":"500 mg of dovitinib (5 capsules) once a day for 5 continuous days and stop for 2 days. Continue to take dovitinib capsules in this manner until progression or unacceptable toxicity develops.","reportingStatus":"POSTED","timeFrame":"From start of treatment, up to 8 weeks","title":"Disease Control Rate","type":"SECONDARY","unitOfMeasure":"participants"}